Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
E2F3 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal, Subcutaneous, Intranasal, Inhalation, Intravenous, Intratumoral, Intrathecal, Intravitreal, Ophthalmic, Topical
01
Overview
E2F3 siRNA is a small interfering RNA designed to silence the expression of the E2F transcription factor 3 (E2F3) gene. It functions through the RNA interference (RNAi) pathway, where it mediates the sequence-specific degradation of E2F3 mRNA, leading to a reduction in E2F3 protein levels. In the context of oncology research, particularly in clear cell renal cell carcinoma (CCC), E2F3 siRNA is used to investigate the role of E2F3 in cell cycle regulation, centrosome amplification, and aneuploidy. Research indicates that downregulation of E2F3, often as a downstream effect of miR-210 upregulation, contributes to chromosomal instability in cancer cells.
02
Targets
E2F3 (Transcription factor E2F3)
Beyond the preview
Go deeper on E2F3 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on E2F3 siRNA.